These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 26614095)

  • 1. Performing Survival Analyses in the Presence of Competing Risks: A Clinical Example in Older Breast Cancer Patients.
    de Glas NA; Kiderlen M; Vandenbroucke JP; de Craen AJ; Portielje JE; van de Velde CJ; Liefers GJ; Bastiaannet E; Le Cessie S
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26614095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cumulative incidence in competing risks data and competing risks regression analysis.
    Kim HT
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):559-65. PubMed ID: 17255278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Competing time-to-event endpoints in cardiology trials: a simulation study to illustrate the importance of an adequate statistical analysis.
    Rauch G; Kieser M; Ulrich S; Doherty P; Rauch B; Schneider S; Riemer T; Senges J
    Eur J Prev Cardiol; 2014 Jan; 21(1):74-80. PubMed ID: 22964966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the Cox model to the Fine-Gray model for survival analyses of re-fracture rates.
    Nolan EK; Chen HY
    Arch Osteoporos; 2020 Jun; 15(1):86. PubMed ID: 32519193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Competing risks analysis of patients with osteosarcoma: a comparison of four different approaches.
    Tai BC; Machin D; White I; Gebski V;
    Stat Med; 2001 Mar; 20(5):661-84. PubMed ID: 11241570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic models with competing risks: methods and application to coronary risk prediction.
    Wolbers M; Koller MT; Witteman JC; Steyerberg EW
    Epidemiology; 2009 Jul; 20(4):555-61. PubMed ID: 19367167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival analysis of women with breast cancer: competing risk models.
    Ferraz RO; Moreira-Filho DC
    Cien Saude Colet; 2017 Nov; 22(11):3743-3754. PubMed ID: 29211179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Introduction to the Analysis of Survival Data in the Presence of Competing Risks.
    Austin PC; Lee DS; Fine JP
    Circulation; 2016 Feb; 133(6):601-9. PubMed ID: 26858290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statistical Methods for Cohort Studies of CKD: Survival Analysis in the Setting of Competing Risks.
    Hsu JY; Roy JA; Xie D; Yang W; Shou H; Anderson AH; Landis JR; Jepson C; Wolf M; Isakova T; Rahman M; Feldman HI;
    Clin J Am Soc Nephrol; 2017 Jul; 12(7):1181-1189. PubMed ID: 28242844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the importance of accounting for competing risks in pediatric cancer trials designed to delay or avoid radiotherapy: I. Basic concepts and first analyses.
    Tai BC; Grundy RG; Machin D
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1493-9. PubMed ID: 19577860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different survival analysis methods for measuring long-term outcomes of Indigenous and non-Indigenous Australian cancer patients in the presence and absence of competing risks.
    He VY; Condon JR; Baade PD; Zhang X; Zhao Y
    Popul Health Metr; 2017 Jan; 15(1):1. PubMed ID: 28095862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis and design of randomised clinical trials involving competing risks endpoints.
    Tai BC; Wee J; Machin D
    Trials; 2011 May; 12():127. PubMed ID: 21595883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Competing events in patients with malignant disease who are at risk for recurrent venous thromboembolism.
    Parpia S; Julian JA; Thabane L; Lee AY; Rickles FR; Levine MN
    Contemp Clin Trials; 2011 Nov; 32(6):829-33. PubMed ID: 21777700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality.
    Solak M; Turkoz FP; Keskin O; Aksoy S; Babacan T; Sarici F; Kertmen N; Sever AR; Altundag K
    J BUON; 2015; 20(3):737-45. PubMed ID: 26214625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Model selection in competing risks regression.
    Kuk D; Varadhan R
    Stat Med; 2013 Aug; 32(18):3077-88. PubMed ID: 23436643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications.
    Varadhan R; Weiss CO; Segal JB; Wu AW; Scharfstein D; Boyd C
    Med Care; 2010 Jun; 48(6 Suppl):S96-105. PubMed ID: 20473207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum enterolactone levels and mortality outcome in women with early breast cancer: a retrospective cohort study.
    Guglielmini P; Rubagotti A; Boccardo F
    Breast Cancer Res Treat; 2012 Apr; 132(2):661-8. PubMed ID: 22094938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An individual person data meta-analysis of preoperative magnetic resonance imaging and breast cancer recurrence.
    Houssami N; Turner R; Macaskill P; Turnbull LW; McCready DR; Tuttle TM; Vapiwala N; Solin LJ
    J Clin Oncol; 2014 Feb; 32(5):392-401. PubMed ID: 24395846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of competing mortality in early breast cancer.
    Mell LK; Jeong JH; Nichols MA; Polite BN; Weichselbaum RR; Chmura SJ
    Cancer; 2010 Dec; 116(23):5365-73. PubMed ID: 20737562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of invasive breast cancer in the presence of competing mortality: the Canadian National Breast Screening Study.
    Taghipour S; Banjevic D; Fernandes J; Miller AB; Montgomery N; Harvey BJ; Jardine AK
    Breast Cancer Res Treat; 2012 Jul; 134(2):839-51. PubMed ID: 22689090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.